"The EpiPen, an easy-to-use injectable shot filled with medicine that can stop a life-threatening allergic reaction, has increased in price from about $100 for a pack of two pens in 2009 to over $600 this year. Pharmaceutical company Mylan purchased the rights to the pen back in 2007, and it appears that they’ve taken a page from “pharma bro” Martin Shkreli and re-priced their newly acquired product. That is, they’ve spiked prices for no apparent research and development reason related to the product, except perhaps to make up for the tens of millions of dollars they’ve spent on TV commercials to promote it, reports CBS news. The price spike also coincides with the recall of one of EpiPen’s competitors, the Auvi-Q from the pharmaceutical company Sanofi US. The company recalled their pen in October because of inaccurate dosage issues... Pharmaceutical watchdogs and politicians have weighed in on the price hike, pushing back on Mylan’s pricing scheme and calling for competitors to enter the market."
Showing posts with label lack of competitors. Show all posts
Showing posts with label lack of competitors. Show all posts
Friday, August 19, 2016
EpiPen’s 500 Percent Price Hike Leaves Patients Scrambling; Huffington Post, 8/18/16
Anna Almendrala, Huffington Post; EpiPen’s 500 Percent Price Hike Leaves Patients Scrambling:
Subscribe to:
Posts (Atom)